EGFR-mediated tumor immunoescape The imbalance between phosphorylated STAT1 and phosphorylated STAT3

OncoImmunology

Volumn 2, Issue 12, 2013, Pages 1-3

  Concha Benavente, Fernando ^a   Srivastava, Raghvendra M ^a   Ferrone, Soldano ^b   Ferris, Robert L ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Apm; Egfr; Immunoescape; Immunotherapy; Pstat1; Pstat3; Shp2

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN GP 130; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; PROTEASOME SUBUNIT BETA TYPE 9; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT1 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CARCINOGENESIS; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; ENZYME INHIBITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOSURVEILLANCE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84896702989     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27215     Document Type: Article

References (13)

1. Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother 2011; 60:525-35; PMID:21207025; http://dx.doi.org/10.1007/s00262-010-0961-7
2. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005; 11:2552-60; PMID:15814633; http:// dx.doi.org/10.1158/1078-0432.CCR-04-2146
3. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 2006; 12:3890-5; PMID:16818683; http:// dx.doi.org/10.1158/1078-0432.CCR-05-2750
4. López-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006; 176:3402-9; PMID:16517708
5. Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, Ferrone S, Ferris RL. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res 2013; 19:798-808; PMID:23363816; http://dx.doi. org/10.1158/1078-0432.CCR-12-1517
6. Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol 2003; 23:7875-86; PMID:14560030; http://dx.doi.org/10.1128/ MCB.23.21.7875-7886.2003
7. Sapkota B, Hill CE, Pollack BP. Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells. Oncoimmunology 2013; 2:e22890; PMID:23483066; http://dx.doi. org/10.4161/onci.22890
8. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest 1998; 102:1385-92; PMID:9769331; http:// dx.doi.org/10.1172/JCI3785
9. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000; 97:4227-32; PMID:10760290; http://dx.doi.org/10.1073/ pnas.97.8.4227
10. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51; PMID:17186030; http://dx.doi. org/10.1038/nri1995
11. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11:1314-21; PMID:16288283; http://dx.doi.org/10.1038/nm1325
12. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10:48-54; PMID:14702634; http://dx.doi.org/10.1038/nm976
13. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 2003; 63:2948-56; PMID:12782602